Laboratory Co. of America Holdings (NYSE:LH) Shares Bought by Fairview Capital Investment Management LLC

Fairview Capital Investment Management LLC lifted its holdings in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 225,840 shares of the medical research company's stock after acquiring an additional 3,978 shares during the quarter. Laboratory Co. of America accounts for about 2.7% of Fairview Capital Investment Management LLC's holdings, making the stock its 13th biggest holding. Fairview Capital Investment Management LLC owned approximately 0.27% of Laboratory Co. of America worth $51,790,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Empowered Funds LLC increased its position in Laboratory Co. of America by 0.5% during the 4th quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company's stock valued at $1,840,000 after purchasing an additional 43 shares during the period. SP Asset Management LLC increased its position in Laboratory Co. of America by 0.3% during the 4th quarter. SP Asset Management LLC now owns 15,186 shares of the medical research company's stock valued at $3,483,000 after purchasing an additional 43 shares during the period. Oppenheimer Asset Management Inc. increased its position in Laboratory Co. of America by 0.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,780 shares of the medical research company's stock valued at $2,931,000 after purchasing an additional 45 shares during the period. Oregon Public Employees Retirement Fund increased its position in Laboratory Co. of America by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,194 shares of the medical research company's stock valued at $1,650,000 after purchasing an additional 46 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its position in Laboratory Co. of America by 16.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 354 shares of the medical research company's stock valued at $81,000 after purchasing an additional 50 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 500 shares of Laboratory Co. of America stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $255.63, for a total transaction of $127,815.00. Following the transaction, the director now owns 13,166 shares of the company's stock, valued at $3,365,624.58. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Amy B. Summy sold 758 shares of Laboratory Co. of America stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $231.67, for a total value of $175,605.86. Following the transaction, the executive vice president now directly owns 5,302 shares in the company, valued at approximately $1,228,314.34. This trade represents a 12.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,987 shares of company stock worth $4,171,895 in the last three months. 0.84% of the stock is owned by company insiders.

Laboratory Co. of America Stock Performance

NYSE:LH traded down $3.00 during trading hours on Friday, reaching $245.76. The company had a trading volume of 583,379 shares, compared to its average volume of 639,717. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The firm has a market cap of $20.57 billion, a PE ratio of 27.86, a price-to-earnings-growth ratio of 1.71 and a beta of 0.82. The business's 50 day moving average price is $233.68 and its 200-day moving average price is $237.03. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.73 by $0.11. The firm had revenue of $3.35 billion during the quarter, compared to analysts' expectations of $3.41 billion. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.68 earnings per share. Research analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America's dividend payout ratio (DPR) is 33.29%.

Analyst Ratings Changes

LH has been the topic of a number of recent research reports. Jefferies Financial Group upped their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Robert W. Baird increased their price objective on shares of Laboratory Co. of America from $253.00 to $267.00 and gave the company an "outperform" rating in a research report on Wednesday, April 30th. StockNews.com downgraded shares of Laboratory Co. of America from a "buy" rating to a "hold" rating in a research report on Friday, April 18th. UBS Group cut their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Finally, Barclays increased their price objective on shares of Laboratory Co. of America from $240.00 to $250.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Laboratory Co. of America currently has a consensus rating of "Moderate Buy" and a consensus price target of $269.38.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.